Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is indicated for 'the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above'.
The dosage schedule is available in the summary of product characteristics for setmelanotide.
The list price of setmelanotide is £2,376.00 per 10 mg/ml vial for injection (excluding VAT; BNF online, accessed July 2023).
The company has a commercial arrangement. This makes setmelanotide available to the NHS with a discount. The size of the discount is commercial in confidence.